Citing “fantastic opportunity,” FDA and EMA call for rigorous science. Agency scientists tell FTD Treatment Study Group: Explore individualized outcomes, and connect biomarkers to meaningful improvement.
Hoping for better luck in clinical trials than their Alzheimer’s colleagues had in the past decade, FTD researchers are now chasing biomarkers. It’s slim pickings so far, but neurofilament, tau PET, and MRI are showing promise.
By examining polymorphisms linked to autoimmune diseases, researchers pinned two loci to Alzheimer’s risk. Both may worsen neurofibrillary tangle pathology.
Exome sequencing in families with amyotrophic lateral sclerosis and frontotemporal dementia yields variants of a gene that helps recycle cellular waste.
At a workshop of the Frontotemporal Dementia Treatment Study Group, advocates and regulatory scientists urged leaders from industry and academia to forge a collaborative approach while the field is still young.
Researchers confirm that new cases of dementia are on the wane in the United Kingdom, with the greatest benefits among older men.
A bit less strapped for funding, researchers are considering the next steps for Lewy body, frontotemporal, and vascular dementia.
NAPA's latest collective exercise was a conference to update the field on progress in the past three years and advise the NIH on how to spend the next round of funds.
Neurogeneticists honored for their discoveries, especially of repeat expansions that cause ALS/FTD.
Scientists report that the transcription factor NRF2 regulates tau expression, stimulating production of a protective isoform.
A NOVA special gets up close and personal with Alzheimer’s researchers and their patients, asking if this disease can be stopped.
Alois was right: Among cognitively normal middle-aged people followed for more than a decade, memory worsened only in those in whom markers for both amyloid and tau were abnormal.
A growing number of studies have hinted that neurogranin may be a promising biomarker for Alzheimer’s disease. How promising? New meta-analyses by Henrik Zetterberg and Bob Olsson suggest that the synaptic protein is elevated nearly twofold in the cerebrospinal fluid of people with Alzheimer’s relative to controls. Baseline levels are also higher in people with MCI who go on to develop Alzheimer’s dementia, compared to those who do not. Plasma levels do not appear to correlate with disease. View the aggregated data and analyses in AlzBiomarker and stay tuned for further additions to the database.
Earlier this month in Washington, D.C., 95 scientists from 23 companies, 19 academic institutions and two regulatory agencies met with funders, advocates, patients, and caregivers. The buzz was all about learning from the mistakes and setbacks of drug development in Alzheimer’s disease and getting a collective act together while the FTD field is still young. What did the group agree on? Basic science and longitudinal human studies are advancing apace, but what the fields needs most urgently to launch more and good trials is a toolbox of biomarkers to subtype FTD disorders and measure target engagement. For their part, the regulators want creative, rigorous science that tries to couple biomarker change to meaningful outcomes, but assured the scientists that no disease is too rare for them to be keenly interested and approve drugs for it. Read Gabrielle Strobel's three-part series.
Did you know the U.S. National Alzheimer’s Project Act covers Lewy body, frontotemporal, vascular, and mixed dementias, as well? It does, and last month, scientists gathered at the National Institutes of Health to powwow about where we are with these disorders and how best to target research dollars to them. Based on this meeting, research leaders articulated funding priorities for each of these diseases, which will inform both the next bypass budget, and, hopefully, the next Congressional funding allocation for research on these less-studied dementing illnesses. The webcasts are live, but are you too busy to listen to two full days talks an discussion? Read Alzforum’s summary of how it all fits together, and then hit play for more detail on the topics that interest you most.
Do you ever wonder what the take-home messages are of the large and growing Alzheimer’s disease biomarker literature? What do we know about CSF Aβ42? Does the research hold up? In the April 8 Lancet Neurology, Bob Olsson, Kaj Blennow, Henrik Zetterberg and colleagues published the most comprehensive survey and meta-analysis of AD fluid biomarkers to date, covering data from a combined total of nearly 30,000 controls and people with MCI or AD. What did they find, and how can their work help your research? Join our webinar on Friday, April 29, at 1 p.m. U.S. Eastern time. Zetterberg will summarize the paper, and Kelly Dakin will show you how to navigate and further explore the data in the AlzBiomarker interactive database. Bob Olsson and Johannes Streffer will join guest moderator Anne Fagan for a panel discussion.
- Maria Teresa Ferretti, M. Florencia Iulita and Sonia Do Carmo on Paper Alert: Microglia Mediate Synaptic Loss in Early Alzheimer’s Disease
- Petra Kashi on New Genetic Method Connects Immune Genes to Alzheimer’s
- Wataru Araki on New Gene Strengthens Link Between ALS and FTD
- John Hardy on New Genetic Method Connects Immune Genes to Alzheimer’s
- Kaj Blennow on CSF Tau Rivals Aβ for Predicting Cognitive Decline
- Walter A. Rocca on Dementia Incidence in Britain Dropped, Mostly in Men
- Chengxuan Qiu on Dementia Incidence in Britain Dropped, Mostly in Men
- Eric Larson on Dementia Incidence in Britain Dropped, Mostly in Men
- Suzanne de la Monte on Diabetic Monkeys Show Signs of Early Alzheimer’s
- Stephen Salloway on CSF Tau Rivals Aβ for Predicting Cognitive Decline
- Timothy Miller on Mexiletine Banishes Muscle Cramps in Phase 2 Trial of ALS